Vertex Pharmaceuticals (VRTX) late Thu. reported a smaller-than-expected Q1 adjusted loss of 65 cents a share. It also said an experimental drug combined with its Kalydeco significantly improved lung function for a certain type of cystic fibrosis in a Phase 3 trial. Shares rose 3% after hours.
- Health Care Industry
- Pharmaceuticals & Drug Trials
- Vertex Pharmaceuticals